To access this element change to forms mode OFF
Grant Award View - GA217910
An early phase, open label, multi-centre trial of front-line TheRapy for...
GA ID:
GA217910
Agency:
Department of Health and Aged Care
Approval Date:
6-Dec-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Feb-2022 to 31-Jan-2027
Value (AUD):
$2,844,744.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas – 2: TREBL-2
Purpose:
In this ground-breaking Australasian Leukaemia Lymphoma Group Phase-1 study, we will use front-line immunotherapy in an innovative trial that targets the unique viral-immuno-biological features of a rare but devastating type of virally driven lymphoma. It is called ‘EBV-associated Diffuse large B-cell lymphoma’. The aim of our proposal is to provide a highly targeted but relatively well-tolerated therapy, that eradicates disease and prevents relapse by restoring immunity.
GO ID:
GO Title:
MRFF 2021 Rare Cancers Rare Diseases Unmet Need General - Grant Opportunity
Internal Reference ID:
2021/MRF2014657
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
St Lucia
Town/City:
St Lucia
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, QLD, TAS
Postcode:
Multiple
Country:
AUSTRALIA